Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Head & Neck 3Genitourinary 3Dermatologic 3Gastrointestinal 2Lymphoid 1Gynecologic 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 4Melanoma 3Lymphoma, Large B-Cell, Diffuse 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Lymphoma, Follicular 2Carcinoma, Renal Cell 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Papillomavirus Infections 1Oropharyngeal Neoplasms 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Advanced/Metastatic Solid Tumors 1Advanced Solid Tumors 1

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236aldesleukin 134Cyclophosphamide 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 67dabrafenib 65fludarabine phosphate 61sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35cobimetinib 32Magnetic Resonance Spectroscopy 32Introns 30Specimen Handling 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Melanoma × utomilumab × Clear all
NCT02554812 2024-07-30

JAVELIN Medley

Pfizer

Phase 1/2 Terminated
409 enrolled 108 charts
BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02315066 2022-04-21

Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566

Pfizer

Phase 1 Completed
174 enrolled 68 charts
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms

NCT01307267 2020-03-17

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Pfizer

Phase 1 Completed
190 enrolled 65 charts
DermatologicGenitourinaryHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡